|Dr. Stephen A. Williams BS, MB, Ph.D.||Chief Medical Officer||648.03k||N/A||1960|
|Mr. Adam Taich||Interim CEO||N/A||N/A||1975|
|Mr. Eliot M. Lurier CPA, CPA||Interim Chief Financial Officer||N/A||N/A||1958|
|Mr. Pi Zheng||Interim Chief Accounting Officer||N/A||N/A||1973|
|Dr. Jason Cleveland Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Dr. Nebojsa Janjic Ph.D.||Chief Science Officer||N/A||N/A||1961|
|Mr. Ruben Gutierrez J.D.||Gen. Counsel||N/A||N/A||1975|
|Ms. Alison Marie Roelke||Chief People Officer||N/A||N/A||1975|
|Dr. Shane Bowen Ph.D.||Chief R&D Officer||N/A||N/A||N/A|
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.
SomaLogic, Inc.’s ISS governance QualityScore as of 1 September 2023 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder rights: 8; Compensation: 9.